Heron Therapeutics: A Great Story Undercut By Its Own Numbers

# Heron Therapeutics: A Great Story Undercut By Its Own Numbers

Here's the thing about guidance withdrawals: companies don't pull them because things are fine. Heron Therapeutics yanked its full-year 2026 outlook after Q2 revenue came in soft, and the culprit — CINVANTI, its largest product — is now bleeding share to branded competition faster than management wants to admit in public. That's the headline. Everything else is commentary.

Let's rewind. Back in Q1, Heron reaffirmed 2026 guidance of $173–$183 million in net revenue and $10–$20 million in Adjusted EBITDA, sounding confident enough. Fast forward one quarter, and that confidence evaporated. CINVANTI sales fell roughly 10% year-over-year in Q2, and the guidance got pulled entirely — not trimmed, not "reaffirmed with caveats," just withdrawn. When a company can't tell you what the rest of the year looks like three months after telling you exactly that, you're allowed to be skeptical.

The Good News Is Actually Good

Buried under the CINVANTI wreckage is a genuinely strong story: the acute care franchise — ZYNRELEF and APONVIE — is compounding nicely. Q2 acute care revenue rose 38% year-over-year to $29 million, following 32% growth in Q1 (ZYNRELEF up 27%, APONVIE up a blistering 50%), which itself followed 65% full-year growth in 2025. That's not noise. That's a real commercial ramp, and it's the part of the bull case that doesn't require squinting.

Heron also cleared a legal overhang, settling CINVANTI patent litigation with Baxter Healthcare around the Q1 release. Good — one less lawyer to worry about. But let's be honest about what that settlement does and doesn't fix: it removes a courtroom risk, not a commercial one. Baxter's lawyers going home doesn't stop CINVANTI's branded competitors from taking share in the market. Those are two entirely separate problems, and only one of them got solved.

The Math Problem Nobody's Solving Yet

Here's where the bull thesis runs into arithmetic. Acute care brought in $29 million in Q2. CINVANTI, even in decline, remains the company's largest revenue line by a wide margin. A 38% growth rate on a smaller base is exciting on a slide deck; it is not yet large enough in dollar terms to backfill what CINVANTI is losing. Until acute care's absolute contribution overtakes CINVANTI's absolute decline, "fastest growing segment" is a talking point, not a turnaround.

Then there's the balance sheet, which is not a strong point in this story. Debt-to-equity sits at an eye-watering ~1550:1, free cash flow is running around -$18.4 million, and — tellingly — an 8-K filed August 10 referenced a Second Amendment, an Exchange Agreement, a 2031 Note Purchase Agreement, and a Purchase Agreement. Translation: Heron is out actively reworking its capital stack. That's not automatically a disaster, but combined with negative cash flow and a company that just admitted it can't forecast its own year, it's not exactly reassuring either. Short interest sitting north of 23% of float tells you the market has already made up its mind on the skeptical side.

Where This Leaves You

There's a real product story here — ZYNRELEF and APONVIE are doing what management hoped, and the Baxter settlement genuinely subtracts a risk. But CINVANTI's erosion is structural, not a one-quarter blip, and it's dragging on the one number that matters most: total revenue predictability. A company that withdraws guidance mid-year while simultaneously papering over its balance sheet with new note and exchange agreements is not a company in a position of strength — it's a company buying time and hoping the acute care ramp gets there before the CINVANTI hole gets too deep.

Watch three things from here: whether Q3 earnings (expected in the October–November window, though no date's been confirmed) bring any hint of reinstated guidance; what those new financing terms actually cost shareholders once the details surface; and whether acute care's dollar growth finally starts outpacing CINVANTI's dollar decline instead of just outpacing it on a percentage chart. Until then, this is a growth story wearing a distressed balance sheet's clothes — and the market, judging by that short interest, isn't buying the costume yet.